Scinai Immunotherapeutics financials
$1.41−4.08%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $1.3M | $658.0K | $0.00 |
| Gross profit | -$2.7M | -$580.0K | $0.00 |
| Gross margin | −202.3% | −88.1% | — |
| Operating income | -$7.5M | -$8.6M | -$9.7M |
| Net income | -$8.3M | $4.8M | -$6.5M |
| Net margin | −633.6% | 728.9% | — |
| Diluted EPS | $0.00 | $0.00 | $0.04 |
| EBITDA | -$6.1M | -$7.0M | -$9.2M |
| Operating cash flow | -$6.0M | -$6.3M | -$9.4M |
| Free cash flow | -$6.1M | -$6.3M | -$10.0M |
| Diluted shares | 933.9M | 322.5M | 156.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $1.7M | $2.0M | $4.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $294.0K | $260.0K | $19.4M |
| Total assets | $11.6M | $13.4M | $17.5M |
| Total liabilities | $3.5M | $3.5M | $22.0M |
| Shareholders' equity | $8.1M | $10.0M | -$4.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology